Skip to main content

Table 1 Characteristics of the 511 diffuse large B-cell lymphoma (DLBCL) patients in the entire cohort and the central nervous system (CNS) relapse cohort (CHOP vs. R-CHOP)

From: New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study

Clinical factor

Entire cohort [cases (%)]

CNS relapse cohort [cases (%)]

CHOP

R-CHOP

P

CHOP

R-CHOP

P

Total

135

376

 

11

14

 

Age

  

0.563

  

1.000

 ≤60 years

98 (72.6)

263 (69.9)

 

8 (72.7)

10 (71.4)

 

 >60 years

37 (27.4)

113 (30.1)

 

3 (27.3)

4 (28.6)

 

Gender

  

0.694

  

0.115

 Male

76 (56.3)

219 (58.2)

 

5 (45.5)

11 (78.6)

 

 Female

59 (43.7)

157 (41.8)

 

6 (54.5)

3 (21.4)

 

Stage

  

0.892

  

0.434

 I or II

77 (57.0)

217 (57.7)

 

5 (45.5)

4 (28.6)

 

 III or IV

58 (43.0)

159 (42.3)

 

6 (54.5)

10 (71.4)

 

B symptoms

  

0.663

  

1.000

 No

95 (70.4)

272 (72.3)

 

7 (63.6)

8 (57.1)

 

 Yes

40 (29.6)

104 (27.7)

 

4 (36.4)

6 (42.9)

 

Bulky diseasea,b

  

0.238

  

0.500

 No

91 (67.4)

252 (67.0)

 

6 (54.5)

8 (57.1)

 

 Yes

10 (7.4)

17 (4.5)

 

0 (0)

2 (14.3)

 

Involved extranodal sitesc

  

0.617

  

0.414

 ≤1

112 (83.0)

303 (80.6)

 

8 (72.7)

7 (50)

 

 >1

23 (17.0)

71 (18.9)

 

3 (27.3)

7 (50)

 

Sinus involvement

  

0.971

  

0.604

 No

119 (88.1)

331 (88.0)

 

10 (90.9)

11 (78.6)

 

 Yes

16 (11.9)

45 (12.0)

 

1 (9.1)

3 (21.4)

 

Bone involvement

  

0.947

  

0.407

 No

120 (88.9)

335 (89.1)

 

9 (81.8)

9 (64.3)

 

 Yes

15 (11.1)

41 (10.9)

 

2 (18.2)

5 (35.7)

 

Bone marrow involvement

  

0.177

  

0.230

 No

133 (98.5)

360 (95.7)

 

11 (100)

11 (78.6)

 

 Yes

2 (1.5)

16 (4.3)

 

0 (0)

3 (21.4)

 

Liver involvement

  

0.792

  

0.487

 No

131 (97.0)

361 (96.0)

 

11 (100)

12 (85.7)

 

 Yes

4 (3.0)

15 (4.0)

 

0 (0)

2 (14.3)

 

Testicular involvement

  

0.526

  

1.000

 No

131 (97.0)

368 (97.9)

 

11 (100)

13 (92.9)

 

 Yes

4 (3.0)

8 (2.1)

 

0 (0)

1 (7.1)

 

Renal involvement

  

0.782

  

0.661

 No

130 (96.3)

360 (95.7)

 

9 (81.8)

10 (71.4)

 

 Yes

5 (3.7)

16 (4.3)

 

2 (18.2)

4 (28.6)

 

Breast involvement

  

0.318

  

–

 No

130 (96.3)

368 (97.9)

 

11 (100)

14 (100)

 

 Yes

5 (3.7)

8 (2.1)

 

0 (0)

0 (0)

 

Female genital tract involvement

  

0.063

  

–

 No

131 (97.0)

373 (99.2)

 

11 (100)

14 (100)

 

 Yes

4 (3.0)

3 (0.8)

 

0 (0)

0 (0)

 

IPI

  

0.096

  

0.208

 0–2

113 (83.7)

289 (76.9)

 

9 (81.8)

7 (50.0)

 

 3–5

22 (16.3)

87 (23.1)

 

2 (18.2)

7 (50.0)

 

LDHd

  

0.768

  

0.677

 ≤1 ULNe

79 (58.5)

215 (57.2)

 

3 (27.3)

6 (42.9)

 

 >1 ULN

55 (40.7)

159 (42.3)

 

8 (72.7)

8 (57.1)

 

ALB

  

0.464

  

0.656

 <35 g/L

114 (84.4)

327 (87.0)

 

4 (36.4)

3 (21.4)

 

 ≥35 g/L

21 (15.6)

49 (13.0)

 

7 (63.6)

11 (78.6)

 

ALPf

  

0.529

  

1.000

 ≤110 U/L

119 (88.1)

341 (90.7)

 

8 (72.7)

10 (71.4)

 

 >110 U/L

15 (11.1)

35 (9.3)

 

3 (27.3)

4 (28.6)

 

IT chemotherapy prophylaxisg

  

0.640

  

0.661

 No

117 (86.7)

329 (87.5)

 

9 (81.8)

10 (71.4)

 

 Yes

18 (13.3)

44 (11.7)

 

2 (18.2)

4 (28.6)

 

TTCh

  

0.016

  

0.003

 ≤108 days

54 (40.0)

207 (55.1)

 

0 (0)

7 (50.0)

 

 >108 days

67 (49.6)

155 (41.2)

 

10 (90.9)

3 (21.4)

 
  1. CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, IPI international prognostic index, LDH lactate dehydrogenase, ULN upper limit of normal, ALB albumin, ALP alkaline phosphatase, IT intrathecal, TTC time to complete remission
  2. aBulky disease: mass ≥7.5 cm
  3. bIn the entire cohort, the data of 34 patients in the CHOP group and seven patients in the R-CHOP group were missing; in the CNS relapse cohort, the data of five patients in the CHOP group and four patients in the R-CHOP group were missing
  4. cIn the entire cohort, the data of two patients in the R-CHOP group were missing
  5. dIn the entire cohort, the data of one patient in the CHOP group and two patients in the R-CHOP group were missing
  6. fIn the entire cohort, the data of one patient in the CHOP group were missing
  7. gIn the entire cohort, the data of three patients in the R-CHOP group were missing
  8. hIn the entire cohort, the data of 14 patients in the CHOP group and 14 patients in the R-CHOP group were missing; in the CNS relapse cohort, the data of one patient in the CHOP group and four patients in the R-CHOP group were missing
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us